Humanigen, Inc. (NASDAQ:HGEN – Get Rating) was the target of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 5,820,000 shares, a drop of 8.3% from the March 31st total of 6,350,000 shares. Based on an average daily volume of 2,540,000 shares, the days-to-cover ratio is currently 2.3 days.

Humanigen Stock Down 5.5 %

Shares of HGEN traded down $0.01 during midday trading on Wednesday, reaching $0.15. 558,878 shares of the stock were exchanged, compared to its average volume of 2,811,466. Humanigen has a 12-month low of $0.09 and a 12-month high of $3.25. The firm has a 50 day simple moving average of $0.15 and a 200-day simple moving average of $0.15. The company has a market cap of $17.85 million, a price-to-earnings ratio of -0.10 and a beta of -0.84.

Analysts Set New Price Targets

HGEN has been the subject of a number of research reports. Credit Suisse Group restated an "underperform" rating and set a $0.50 price objective on shares of Humanigen in a research report on Monday, April 3rd. Cantor Fitzgerald initiated coverage on Humanigen in a research report on Wednesday, January 11th. They set a "neutral" rating for the company.

Institutional Investors Weigh In On Humanigen

A number of hedge funds and other institutional investors have recently made changes to their positions in HGEN. JPMorgan Chase & Co. raised its stake in shares of Humanigen by 35.9% in the 1st quarter. JPMorgan Chase & Co. now owns 23,163 shares of the company's stock valued at $70,000 after acquiring an additional 6,120 shares in the last quarter. Virtu Financial LLC raised its stake in shares of Humanigen by 71.3% in the 1st quarter. Virtu Financial LLC now owns 37,463 shares of the company's stock valued at $113,000 after acquiring an additional 15,588 shares in the last quarter. Swiss National Bank raised its stake in shares of Humanigen by 15.4% in the 1st quarter. Swiss National Bank now owns 120,700 shares of the company's stock valued at $363,000 after acquiring an additional 16,100 shares in the last quarter. BlackRock Inc. raised its stake in shares of Humanigen by 0.7% in the 1st quarter. BlackRock Inc. now owns 3,367,015 shares of the company's stock valued at $10,136,000 after acquiring an additional 23,215 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Humanigen in the 1st quarter valued at approximately $111,000. 6.93% of the stock is owned by hedge funds and other institutional investors.

About Humanigen

(Get Rating)

Humanigen, Inc, a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH.

Featured Stories

• Get a free copy of the StockNews.com research report on Humanigen (HGEN)
• Starbucks Stock Becomes a Value Play
• Kraft Heinz Recovery Gains Momentum
• Here's Why AMD's Weak Guidance Is A Blessing In Disguise
• BP Shares Sold Off After Earnings: Here Is What Upset Markets
• Will Forced Divesture Of Grail Boost Illumina Shareholder Value?

Receive News & Ratings for Humanigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humanigen and related companies with MarketBeat.com's FREE daily email newsletter.